GEN Exclusives

More »

GEN News Highlights

More »
Jan 17, 2007

Bayer Schering Taps VTT to Study Cancer Drug

  • VTT and Bayer Schering Pharma will collaborate to study the mode of action of a Bayer’s new cancer drug. As part of this two-year research contract, VTT will use its new gene and cell biology methods.

    VTT’s focus is on identifying primary driver genes and targets of genetic alterations in cancer. The company also works toward finding drug compounds preventing the growth and metastasis of breast and prostate cancer.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?